, Volume 22, Issue 6, pp 347-354
Date: 24 Aug 2012

Effect of Metformin on Blood Pressure

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Objective: To evaluate the effect of metformin on blood pressure and insulin sensitivity in non-diabetic, moderately obese, hypertensive patients.

Patients and methods: An 8-week double-blind, placebo-controlled randomised study with a 4-week placebo run-in period was performed. Euglycaemic hyperinsulinaemic clamp tests and 24-hour ambulatory blood pressure measurements were performed after the 4-week placebo run-in period and after the 8-week double-blind treatment in patients in either the metformin 1500mg a day (n = 11) or corresponding placebo (n = 10) group.

Results: Metformin administration did not decrease either 24-hour ambulatory or office blood pressure when compared with placebo. The office mean systolic/ diastolic (±standard deviation) blood pressures before and after treatments were 153 (±22)/96 (±4)mm Hg and 155 (±14)/94 (+6)mm Hg in the metformin group, and 153 (±30)/97 (± 9)mm Hg and 149 (± 18)/96 (± 9)mm Hg in the placebo group, respectively. Metformin significantly decreased fasting serum glucose concentrations from 5.7 (± 0.9) to 5.2 (± 0.4) mmol/L (p = 0.04), but did not affect the insulin sensitivity of the patients.

Conclusions: Metformin does not appear to have a place in the treatment of hypertension in non-diabetic individuals, at least in those with mild hypertension.